Skip to content
drillr.ai
Sign up

ASMB

ASSEMBLY BIOSCIENCES, INC.

NASDAQ · Healthcare · Biotechnology · US

$24.97
−1.46%
Ask drillr

  • Sep 8, 2026, 20:00 UTC

    Assembly Biosciences exercised its U.S. profit-share option with Gilead Sciences for its HSV helicase-primase inhibitor program, agreeing to share 40% of U.S. development costs and profits.

    Source:

  • Aug 13, 2026, 22:16 UTC

    Assembly Biosciences reported a Q2 2026 loss of $0.20 per share, beating the Zacks Consensus Estimate of a $0.70 loss and improving from a $1.33 loss a year earlier.

    Source:

  • Jun 5, 2026, 00:00 UTC

    Assembly Biosciences, Inc. elected Anthony E. Altig, Tomas Cihlar, Gina Consylman, Robert D. Cook II, and Sir Michael Houghton as directors effective June 4, 2026.